Insulet - PODD Stock Forecast, Price & News

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PODD shares.
View PODD analyst ratings or view top-rated stocks.

12 analysts have issued 1-year price objectives for Insulet's stock. Their PODD share price forecasts range from $235.00 to $350.00. On average, they expect the company's share price to reach $292.33 in the next year. This suggests a possible upside of 27.4% from the stock's current price.
View analysts price targets for PODD or view top-rated stocks among Wall Street analysts.

Insulet's stock was trading at $266.07 at the start of the year. Since then, PODD stock has decreased by 13.8% and is now trading at $229.40.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our PODD earnings forecast.

Insulet will be holding an earnings conference call on Thursday, November 3rd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Insulet Co. (NASDAQ:PODD) posted its quarterly earnings results on Thursday, August, 4th. The medical instruments supplier reported ($0.06) EPS for the quarter, missing analysts' consensus estimates of $0.21 by $0.27. The medical instruments supplier earned $299.40 million during the quarter, compared to analyst estimates of $290.87 million. Insulet had a net margin of 2.94% and a trailing twelve-month return on equity of 13.83%. The business's revenue was up 13.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.10 earnings per share.

Insulet updated its third quarter 2022 earnings guidance on Thursday, August, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $322.45 million-$330.72 million, compared to the consensus revenue estimate of $309.85 million.

61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD).

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PODD stock can currently be purchased for approximately $229.40.

Insulet (NASDAQ:PODD) has a market capitalization of $15.92 billion and generates $1.10 billion in revenue each year. The medical instruments supplier earns $16.80 million in net income (profit) each year or $0.50 on an earnings per share basis.

The company employs 2,300 workers across the globe.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The official website for the company is www.insulet.com. The medical instruments supplier can be reached via phone at (978) 600-7000, via email at ir@insulet.com, or via fax at 978-600-0120.